2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …
academic working group of experts aimed at establishing global consensus for the treatment …
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report
Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …
[HTML][HTML] Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
RD McBane II, WE Wysokinski… - Journal of thrombosis …, 2020 - Elsevier
Background Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐
associated venous thromboembolism (VTE). While apixaban is approved for the treatment of …
associated venous thromboembolism (VTE). While apixaban is approved for the treatment of …
Apixaban for the treatment of venous thromboembolism associated with cancer
G Agnelli, C Becattini, G Meyer, A Muñoz… - … England Journal of …, 2020 - Mass Medical Soc
Background Recent guidelines recommend consideration of the use of oral edoxaban or
rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However …
rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However …
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The …
SV Konstantinides, G Meyer, C Becattini… - European heart …, 2020 - academic.oup.com
determination and the implementation of preventive, diagnostic or therapeutic medical
strategies. However, the ESC Guidelines do not override in any way whatsoever the …
strategies. However, the ESC Guidelines do not override in any way whatsoever the …
Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial …
AM Young, A Marshall, J Thirlwall… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term
daily subcutaneous low molecular weight heparin has been standard treatment for such …
daily subcutaneous low molecular weight heparin has been standard treatment for such …
[HTML][HTML] Edoxaban for the treatment of cancer-associated venous thromboembolism
GE Raskob, N Van Es, P Verhamme… - … England Journal of …, 2018 - Mass Medical Soc
Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …
2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing …
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …